PMC:7696151 / 30044-30389
Annnotations
LitCovid-PubTator
Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
---|---|---|---|---|---|
904 | 66-74 | Species | denotes | patients | Tax:9606 |
947 | 139-142 | Chemical | denotes | HCQ | MESH:D006886 |
948 | 154-157 | Chemical | denotes | AZM | MESH:D017963 |
949 | 328-331 | Chemical | denotes | HCQ | MESH:D006886 |
950 | 336-339 | Chemical | denotes | AZM | MESH:D017963 |
987 | 48-56 | Disease | denotes | COVID-19 | MESH:C000657245 |
988 | 57-65 | Disease | denotes | infected | MESH:D007239 |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T207 | 0-345 | Sentence | denotes | In particular, a prospective study on 11 severe COVID-19 infected patients treated with the same dosage used by Gautret et al. (600 mg/day HCQ and 500 mg AZM for the first day followed by 250 mg/day from day 2 to 5) was shown to provide no evidence of clinical benefits or a strong antiviral activity through the combination of HCQ and AZM [34]. |